Rare Strength

An international biopharmaceutical company specialising in rare diseases

We bring something rare to rare diseases – the strength of focus, the power of partnership and the agility to innovate. We believe in the potential of the people we are dedicated to serving.

Download the complete report

Increasing speed

»2019 was a rewarding year in which we made major progress in every area of our strategy. We ended the year as a stronger company with a broader geographical footprint and exceptional value in both our on-market and pre-market portfolios.«

Guido Oelkers, CEO

Read the full CEO letter

2019 in Brief

Our growth journey continued at speed during 2019 as significant acquisitions drove the ongoing transformation of the company. A sharper focus in R&D, broader geographical footprint and two strong therapeutic areas position us well for continued strong growth.

Watch our video looking back on 2019

XX

SEK M in revenue

+ XX %

Revenue growth 2019

XX

Patients in over 70 countries

XX

SEK M in adjusted EBITA

+ XX %

EBITA growth

XX

Full-time employees

Our Business Model

Sobi’s value chain spans from late-stage clinical research and development to commercialisation and patient access to treatments. Our strengths include evaluating and developing late-stage projects, commercialisation and getting treatments to the patients as quickly as possible.

Our Strategy

Our strategy established in 2017 remains in place, with refinements reflecting the evolution of the company. 2019 was a rewarding year in which we made major progress in every area of our strategy. We ended the year as a stronger company with a broader geographical footprint and exceptional value in both our on-market and pre-market portfolios.

Our Therapeutic Areas

The creation of a strong second leg in Immunology balances our success in Haematology and haemophilia.

Haematology

Building on our success in haemophilia, we have expanded the therapeutic area to encompass haematology, and create a platform for long-term growth.

Read more about Haematology

Immunology

With three strongly growing products that each address high unmet medical needs, our Immunology portfolio represents a new focus that builds on our heritage in rare diseases.

Read more about Immunology

Specialty Care

During 2019, we have streamlined our Specialty Care portfolio in line with our sharpened strategic focus.

Read more about Specialty Care

Share of total revenue, by therapeutic area

13%

Specialty Care

Share of total revenue, by therapeutic area

33%

Immunology

54%

Haematology

33%

Immunology

Sustainability

Enabling access to safe and effective treatments is our key contribution to sustainable development. Our sustainability strategy consists of three key initiatives aiming towards increased patient access to treatment.